Rosetta Genomics Signs Two Deals for MicroRNA Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced two collaborations to advance its microRNA-based diagnostic tests.

The Rehovot, Israel-based company has signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both also based in Israel, to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.